Comparison · NCT04308668-sae
Treatment vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Treatment vs Placebo: serious adverse events. Trial comparisons, record NCT04308668-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04308668-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00912 | 0.00419 | 0.0197 | wilson | |
| Risk in group 2 | 0.0168 | 0.00942 | 0.0299 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0077 | -0.0216 | 0.00525 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.542 | 0.202 | 1.46 | log | |
| Odds ratio, group 1 over group 2 | 0.538 | 0.198 | 1.46 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Treatment than on Placebo | 130 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Treatment | Participants in this arm will receive the study drug.~Hydroxychloroquine: 200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days | 6 | 658 | EG000 |
| Group 2 | Placebo | Participants in this arm will receive a placebo treatment.~Placebo: 4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days | 11 | 654 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Approximately 30-days
Source ClinicalTrials.gov
Trial
- Title
- Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2
- NCT number
- NCT04308668
- Phases
- PHASE3
- Conditions
- Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection, Coronavirus, Coronavirus Infections
- Interventions
- Hydroxychloroquine, Placebo
- Lead sponsor
- University of Minnesota
- Results first posted
- 2021-05-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04308668?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04308668-sae